“The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration” (2024) Ukrainian Journal of Ophthalmology , (3), pp. 28–32. doi:10.31288/oftalmolzh202432832.